PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
Open Access
- 10 February 2024
- journal article
- review article
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-16
Abstract
Background: Neovascular eye disease is characterized by pathological neovascularization, with clinical manifestations such as intraocular exudation, bleeding, and scar formation, ultimately leading to blindness in millions of individuals worldwide. Pathologic ocular angiogenesis often occurs in common fundus diseases including proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Anti-vascular endothelial growth factor (VEGF) targets the core pathology of ocular angiogenesis. Main body: In recent years, therapies targeting metabolism to prevent angiogenesis have also rapidly developed, offering assistance to patients with a poor prognosis while receiving anti-VEGF therapy and reducing the side effects associated with long-term VEGF usage. Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key enzyme in targeted metabolism, has been shown to have great potential, with antiangiogenic effects and multiple protective effects in the treatment of neovascular eye disease. In this review, we summarize the mechanisms of common types of neovascular eye diseases; discuss the protective effect and potential mechanism of targeting PFKFB3, including the related inhibitors of PFKFB3; and look forward to the future exploration directions and therapeutic prospects of PFKFB3 in neovascular eye disease. Conclusion: Neovascular eye disease, the most common and severely debilitating retinal disease, is largely incurable, necessitating the exploration of new treatment methods. PFKFB3 has been shown to possess various potential protective mechanisms in treating neovascular eye disease. With the development of several drugs targeting PFKFB3 and their gradual entry into clinical research, targeting PFKFB3-mediated glycolysis has emerged as a promising therapeutic approach for the future of neovascular eye disease.Keywords
Funding Information
- National Natural Science Foundation of China (Grant No.81970812)
This publication has 128 references indexed in Scilit:
- Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell ProliferationAnnual Review of Cell and Developmental Biology, 2011
- A Potential Role for Angiopoietin 2 in the Regulation of the Blood–Retinal Barrier in Diabetic RetinopathyInvestigative Ophthalmology & Visual Science, 2011
- Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin ChemotherapyCancer Research, 2010
- Endothelial cells dynamically compete for the tip cell position during angiogenic sproutingNature Cell Biology, 2010
- Notch regulates the angiogenic response via induction of VEGFR-1Journal of Angiogenesis Research, 2010
- Neurodegeneration: An early event of diabetic retinopathyWorld Journal of Diabetes, 2010
- Stabilization of the retinal vascular network by reciprocal feedback between blood vessels and astrocytesDevelopment, 2005
- Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survivalDevelopmental Biology, 2003
- Endothelial-pericyte interactions in angiogenesisCell and tissue research, 2003
- VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodiaJournal of Cell Biology, 2003